# HLA-A: Major Histocompatibility Complex Class I Heavy Chain, Antigen Presentation, and CD8+ T-Cell Recognition


## Key Takeaways

- HLA-A, a major histocompatibility complex class I heavy chain, presents endogenously derived peptides (8-10 amino acids) to CD8+ cytotoxic T lymphocytes (CTLs) via its polymorphic peptide-binding groove, crucial for immune surveillance against intracellular pathogens and neoplastic transformation.
- The extraordinary allelic diversity of *HLA-A* (over 7,500 alleles) is concentrated in exons encoding the peptide-binding domains (exons 2 and 3), reflecting balancing selection and underpinning population-level resilience against pathogen evasion, but also contributing to alloreactivity in transplantation and disease susceptibility.
- HLA-A expression is tightly regulated by promoter elements (SXY module, ISRE, NF-κB sites) and is upregulated by interferons and pro-inflammatory cytokines, while its presentation pathway involves proteasomal degradation, TAP transport into the ER, and loading onto the heavy chain within the peptide-loading complex.
- Viral pathogens employ sophisticated evasion strategies, such as HIV-1 Nef and HCMV US2/US3/US6/US11, to downregulate HLA-A surface expression or inhibit its antigen presentation pathway, thereby escaping CTL recognition.
- Specific *HLA-A* alleles are established pharmacogenomic biomarkers for severe drug hypersensitivity reactions, notably HLA-A*31:01 with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and HLA-A*32:01 with vancomycin-induced DRESS.
- Therapeutic strategies, including immune checkpoint inhibitors and TCR-engineered T-cell therapies, rely on HLA-A-mediated presentation of tumor-associated antigens; conversely, loss-of-function mutations in *HLA-A* or *B2M* are associated with resistance to these immunotherapies.

---

## Executive Summary & Key Metadata

The *HLA-A* gene encodes the heavy chain (alpha chain) of the human leukocyte antigen (HLA) class I molecule, a polymorphic transmembrane glycoprotein central to adaptive immunity. HLA-A presents endogenously derived peptide antigens (8–10 amino acids) to CD8+ cytotoxic T lymphocytes (CTLs), thereby enabling immune surveillance against intracellular pathogens and neoplastic transformation. The extraordinary allelic diversity of *HLA-A*—with over 7,000 known alleles—confers population-level resilience against pathogen evasion but also underpins alloreactivity in transplantation and associations with autoimmune and infectious disease susceptibility.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | HLA-A |
| **UniProt Accession** | P01892 |
| **Representative PDB ID** | 1HHK (HLA-A*0201 complexed with a nonapeptide) |
| **Chromosomal Locus** | 6p21.33 (MHC class I region) |
| **Primary Molecular Function** | Peptide antigen binding and presentation to CD8+ T cells; initiation of cytotoxic immune responses |
| **Disease & Pathology Associations** | Graft rejection, graft-versus-host disease (GVHD), HIV/AIDS progression, autoimmune disorders (e.g., Behçet's disease, vitiligo), infectious disease susceptibility (tuberculosis, malaria), and cancer immunoediting |

The HLA-A molecule functions as a trimeric complex comprising the polymorphic heavy chain (encoded by *HLA-A*), the invariant β2-microglobulin (β2m, encoded by *B2M* on chromosome 15), and a bound peptide antigen. The heavy chain is organized into three extracellular domains (α1, α2, α3), a transmembrane segment, and a short cytoplasmic tail. The α1 and α2 domains fold to form the peptide-binding groove, a platform of eight antiparallel β-strands topped by two α-helices. This groove accommodates peptides anchored at defined positions (P2 and P9 for HLA-A*02:01), a feature exploited in epitope prediction algorithms and vaccine design [1, 2].

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

*HLA-A* resides within the major histocompatibility complex (MHC) class I region on the short arm of chromosome 6 at cytogenetic band 6p21.33. The MHC spans approximately 3.6 megabases and is subdivided into three regions: class I (telomeric), class III (central), and class II (centromeric). The class I region contains the classical transplantation antigens *HLA-A*, *HLA-B*, and *HLA-C*, as well as non-classical genes *HLA-E*, *HLA-F*, and *HLA-G* [<a href="#ref-3">3</a>]. The genomic coordinates for *HLA-A* (GRCh38/hg38) are approximately chr6:29,942,066–29,945,885 (plus strand), encompassing roughly 3.8 kilobases of genomic DNA. The gene comprises 8 exons and 7 introns, with the coding sequence distributed across exons 1–5 and 8, while exons 6 and 7 are partially translated.

The *HLA-A* gene structure is as follows:

- **Exon 1**: Encodes the leader peptide (signal sequence) of 24 amino acids, which directs the nascent polypeptide into the endoplasmic reticulum (ER) lumen.
- **Exon 2**: Encodes the α1 domain (amino acids 25–114 of the mature protein), contributing half of the peptide-binding groove.
- **Exon 3**: Encodes the α2 domain (amino acids 115–206), completing the peptide-binding groove.
- **Exon 4**: Encodes the α3 domain (amino acids 207–297), an immunoglobulin-like constant domain that binds CD8.
- **Exon 5**: Encodes the transmembrane region (amino acids 298–323), a hydrophobic α-helix anchoring the molecule to the plasma membrane.
- **Exons 6 and 7**: Encode the cytoplasmic tail (amino acids 324–365), containing phosphorylation sites and endocytosis motifs.
- **Exon 8**: Contains the 3' untranslated region (UTR) and polyadenylation signal.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *HLA-A* promoter is a TATA-less, initiator (Inr)-driven promoter located approximately 200 base pairs upstream of the transcription start site (TSS). Key regulatory elements include:

- **SXY module**: A conserved regulatory module (S, X1, X2, and Y boxes) located between −200 and −50 bp upstream of the TSS. The X1 box binds regulatory factor X (RFX) complex, the X2 box binds cAMP-responsive element-binding protein (CREB)/activating transcription factor (ATF), and the Y box binds nuclear transcription factor Y (NF-Y). Together, these elements form an enhanceosome that recruits the class II transactivator (CIITA) in a cell-type-specific manner, although CIITA primarily regulates class II genes, it also modulates class I expression in some contexts.
- **Interferon-stimulated response element (ISRE)**: Located upstream of the SXY module, this element binds interferon regulatory factors (IRF1, IRF2) and signal transducer and activator of transcription 1 (STAT1) in response to type I and type II interferons (IFN-α/β and IFN-γ), driving robust transcriptional upregulation during inflammation.
- **NF-κB binding sites**: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) binds to cognate motifs in the promoter, linking HLA-A expression to pro-inflammatory cytokine signaling (e.g., tumor necrosis factor-alpha, TNF-α).
- **Enhancer elements**: A distal enhancer region located approximately 1 kb upstream contains binding sites for the transcription factors SP1 and AP-1, contributing to basal transcriptional activity.

### 1.3 Allelic Diversity and Haplotype Structure

*HLA-A* is among the most polymorphic genes in the human genome, with the IPD-IMGT/HLA database (release 3.52.0) cataloging over 7,500 alleles. Polymorphisms are concentrated in exons 2 and 3, which encode the peptide-binding domains, reflecting balancing selection driven by pathogen diversity. Alleles are named according to the WHO HLA Nomenclature Committee system, with four-digit resolution indicating distinct protein products (e.g., HLA-A*02:01) and six-to-eight-digit resolution distinguishing synonymous or non-coding variants.

Population-specific allele distributions have been documented extensively. For example, HLA-A*02:01 is the most common allele in Caucasian populations (allele frequency ~27%), whereas HLA-A*11:01 predominates in East Asian populations (allele frequency ~30%). A study of the Punjab population in Pakistan reported HLA-A*02 as the most frequent allele (22.2%), followed by HLA-A*11 (13.4%) and HLA-A*24 (11.1%) [<a href="#ref-4">4</a>]. Such population-specific distributions have implications for transplant matching and epitope-based vaccine design.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *HLA-A* generates multiple mRNA isoforms, although the functional significance of most remains incompletely characterized. The primary transcript undergoes canonical splicing to yield the full-length membrane-bound heavy chain. Additionally, the following isoforms have been described:

- **Soluble HLA-A (sHLA-A)**: Generated by alternative splicing that skips exon 5 (transmembrane domain), producing a secreted form lacking the membrane anchor. sHLA-A is detectable in serum and plasma, with elevated levels observed in inflammatory conditions, transplantation rejection, and certain malignancies. The functional role of sHLA-A includes immune modulation, potentially inducing apoptosis in activated CD8+ T cells via Fas/FasL interactions.
- **Truncated isoforms**: Splicing variants that retain intronic sequences or skip exons 6–7 produce C-terminally truncated heavy chains. These isoforms may be retained in the ER or targeted for proteasomal degradation, potentially serving as a source of HLA-A-derived peptides presented by other class I molecules.
- **N-terminally extended isoforms**: Rare splice variants utilizing alternative upstream TSSs or retaining exon 1-derived sequences produce leader-extended proteins, whose functional relevance is unclear.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The HLA-A heavy chain (UniProt P01892) is a type I transmembrane glycoprotein of 365 amino acids (mature protein: 341 amino acids after signal peptide cleavage). The three-dimensional structure, first solved by X-ray crystallography for HLA-A*02:01 complexed with an influenza matrix peptide (PDB: 1HHK), reveals a modular architecture:

- **α1 domain (residues 1–90 of mature protein)**: Comprises a four-stranded antiparallel β-sheet (β1–β4) followed by a long α-helix (α1 helix). The β-sheet forms the floor of the peptide-binding groove, while the α1 helix forms one wall.
- **α2 domain (residues 91–182)**: Adopts a similar topology to α1, with a four-stranded β-sheet and an α2 helix. The α2 helix forms the opposite wall of the peptide-binding groove. The α1 and α2 helices together create a closed groove approximately 30 Å long, 12 Å wide, and 8 Å deep, accommodating peptides of 8–10 residues.
- **α3 domain (residues 183–274)**: An immunoglobulin-like constant domain with a β-sandwich fold (two antiparallel β-sheets). This domain contains the CD8 binding loop (residues 223–229), which interacts with the CD8α chain on T cells, stabilizing the TCR–pMHC interaction.
- **Transmembrane domain (residues 275–297)**: A hydrophobic α-helix spanning the lipid bilayer, anchoring the heavy chain to the cell surface.
- **Cytoplasmic tail (residues 298–341)**: Contains phosphorylation sites (Ser335, Ser338) and a di-leucine motif (Leu339-Leu340) involved in endocytosis and intracellular trafficking.

### 2.2 Peptide-Binding Groove Architecture

The peptide-binding groove is the defining structural feature of HLA-A. It is composed of six binding pockets (A–F) that accommodate peptide side chains:

- **Pocket A**: Located at the N-terminus of the groove, binds the free amino group of the peptide (P1). Highly conserved across class I molecules.
- **Pocket B**: Binds the P2 anchor residue. For HLA-A*02:01, this pocket is hydrophobic, preferring leucine or methionine. Polymorphic residues at positions 7, 9, 24, 34, 45, 63, 66, 67, 70, and 99 determine pocket B specificity.
- **Pocket C**: Binds the P6 residue, contributing to peptide specificity.
- **Pocket D**: Binds the P3 residue, with moderate polymorphism.
- **Pocket E**: Binds the P7 residue, influencing peptide conformation.
- **Pocket F**: Located at the C-terminus of the groove, binds the P9 anchor residue. For HLA-A*02:01, this pocket is also hydrophobic, preferring valine or leucine. Polymorphic residues at positions 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147 determine pocket F specificity.

The peptide is bound in an extended conformation, with the N- and C-termini fixed by conserved hydrogen-bond networks involving tyrosine residues (Tyr7, Tyr59, Tyr84, Tyr123, Tyr159, Tyr171) and the peptide backbone. This "anchor-based" binding mode allows a single HLA-A allele to present thousands of different peptides sharing only 2–3 anchor residues, a property exploited in computational epitope prediction [1, 2].

### 2.3 Glycosylation and Post-Translational Modifications

HLA-A heavy chain is N-glycosylated at Asn86 (within the α1 domain), with a high-mannose glycan added co-translationally in the ER. This glycan is processed to a complex-type oligosaccharide in the Golgi apparatus before cell-surface expression. Glycosylation is essential for proper folding and ER exit; inhibition of N-linked glycosylation (e.g., by tunicamycin) results in ER retention and degradation of the heavy chain.

Additional post-translational modifications include:

- **Phosphorylation**: Serine residues in the cytoplasmic tail (Ser335, Ser338) are phosphorylated by protein kinase C (PKC) and casein kinase II (CK2), modulating endocytosis and intracellular trafficking.
- **Palmitoylation**: Cys337 in the cytoplasmic tail can be palmitoylated, anchoring the tail to the inner leaflet of the plasma membrane and influencing membrane microdomain localization.
- **Ubiquitination**: Lysine residues in the cytoplasmic tail can be ubiquitinated, targeting the molecule for endosomal degradation, a mechanism exploited by viral immune evasion proteins (e.g., HIV-1 Nef).

### 2.4 Structural Comparison with Other Class I Molecules

HLA-A shares ~85% sequence identity with HLA-B and ~80% with HLA-C in the α1–α3 domains. The overall fold is conserved, but key differences exist in the peptide-binding groove:

- **HLA-B**: Generally has a more hydrophobic pocket B, preferring proline or alanine at P2.
- **HLA-C**: Has a narrower groove due to a tryptophan at position 97, restricting peptide length to 8–9 residues. HLA-C also serves as a ligand for killer-cell immunoglobulin-like receptors (KIRs), a function not shared by HLA-A.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load HLA-A (PDB: 1HHK)](/tools/protein-structure-viewer?source=direct&pdbId=1HHK)

The interactive visualizer allows exploration of the HLA-A*02:01 structure in atomic detail. Users can:

- Rotate and zoom the trimeric complex (heavy chain, β2m, peptide).
- Color domains by secondary structure (α1: red, α2: blue, α3: green, β2m: yellow, peptide: magenta).
- Display the peptide-binding groove surface with electrostatic potential.
- Highlight anchor residues (P2 and P9) and CD8 binding loop.
- Superimpose allelic variants (e.g., HLA-A*11:01, PDB: 1X7Q) to visualize polymorphic differences.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Antigen Processing and Loading Pathway

The HLA-A antigen presentation pathway is a multi-step process that ensures the display of intracellular protein fragments at the cell surface. The pathway can be summarized as follows:

1. **Proteasomal degradation**: Cytosolic proteins are ubiquitinated and degraded by the 26S proteasome, generating peptide fragments of 8–16 amino acids. The immunoproteasome, induced by IFN-γ, contains alternative catalytic subunits (β1i/LMP2, β2i/MECL-1, β5i/LMP7) that enhance cleavage after hydrophobic and basic residues, favoring MHC class I binding.
2. **Peptide transport**: Peptides are translocated into the ER lumen by the transporter associated with antigen processing (TAP), a heterodimeric ABC transporter (TAP1/TAP2). TAP preferentially transports peptides of 8–16 residues with hydrophobic or basic C-termini.
3. **Peptide loading complex (PLC)**: In the ER, the PLC assembles, comprising TAP, tapasin, calreticulin, ERp57, and the chaperone BiP. Tapasin stabilizes the empty HLA-A heavy chain–β2m dimer, facilitates peptide editing (selection of high-affinity peptides), and retains the complex in the ER until a suitable peptide is bound.
4. **Peptide editing and quality control**: Tapasin and ERp57 mediate peptide exchange, favoring peptides with slow off-rates (high affinity). The final peptide–MHC class I (pMHC) complex is released from the PLC and exported to the Golgi via COPII-coated vesicles.
5. **Cell-surface expression**: The mature pMHC complex is transported to the plasma membrane, where it presents the peptide to CD8+ T cells.

```mermaid
sequenceDiagram
    participant R as "Ribosome"
    participant C as "Cytosolic Protein"
    participant P as "Proteasome"
    participant T as "TAP"
    participant E as "ER Lumen"
    participant L as "PLC (Tapasin/Calreticulin/ERp57)"
    participant H as "HLA-A Heavy Chain + β2m"
    participant G as "Golgi"
    participant M as "Plasma Membrane"
    participant Tcell as "CD8+ T Cell"
    R->>C: Translation of protein
    C->>P: Ubiquitination & degradation
    P->>T: Peptide fragments (8-16 aa)
    T->>E: ATP-dependent translocation
    E->>L: Peptide loading onto HLA-A
    L->>H: Peptide editing (tapasin)
    H->>G: COPII vesicle transport
    G->>M: Exocytosis
    M->>Tcell: pMHC presentation
    Tcell->>Tcell: TCR engagement & activation
```

### 3.2 T-Cell Receptor Engagement and Signaling

The pMHC complex on the antigen-presenting cell (APC) surface is recognized by the T-cell receptor (TCR) on CD8+ T cells. The TCR–pMHC interaction is characterized by low affinity (Kd ~1–100 μM) and fast off-rates, enabling serial engagement of multiple TCRs by a single pMHC complex. The CD8 co-receptor binds to the α3 domain of HLA-A, stabilizing the interaction and recruiting the Src kinase Lck to the TCR signaling complex.

TCR engagement triggers a signaling cascade:

1. **Lck activation**: CD8-bound Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3ζ and CD3ε/γ/δ chains.
2. **ZAP-70 recruitment**: Syk family kinase ZAP-70 binds to phosphorylated ITAMs via its tandem SH2 domains and is activated by Lck-mediated phosphorylation.
3. **Adapter protein phosphorylation**: ZAP-70 phosphorylates LAT (linker for activation of T cells) and SLP-76, nucleating a signaling complex that activates phospholipase C-γ1 (PLC-γ1).
4. **Calcium flux and MAPK activation**: PLC-γ1 cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the ER, activating calcineurin and NFAT. DAG activates protein kinase C-θ (PKC-θ) and the Ras-MAPK pathway, leading to AP-1 activation.
5. **Transcriptional activation**: NFAT, AP-1, and NF-κB cooperate to induce genes encoding cytokines (IL-2, IFN-γ), cytolytic molecules (perforin, granzyme B), and survival factors, driving CTL effector function.

### 3.3 Cross-Presentation and CD8+ T-Cell Priming

While HLA-A presents endogenous peptides, professional APCs (dendritic cells) can also present exogenous antigens on class I molecules via cross-presentation. This process involves:

- **Phagosomal pathway**: Exogenous antigens are internalized into phagosomes, where they are degraded by proteases and transported into the cytosol for proteasomal processing, followed by TAP-dependent loading onto HLA-A.
- **Vacuolar pathway**: Antigens are degraded within endosomal compartments and loaded onto recycling HLA-A molecules.

Cross-presentation is essential for priming CD8+ T-cell responses against viruses that do not infect APCs and against tumor antigens.

### 3.4 NK Cell Regulation

Although HLA-A primarily interacts with TCRs, it also serves as a ligand for inhibitory receptors on natural killer (NK) cells, including:

- **KIR3DL2**: Binds HLA-A*03 and HLA-A*11 alleles, delivering inhibitory signals that prevent NK cell-mediated lysis of healthy cells.
- **LILRB1 (ILT2)**: Binds HLA-A in complex with β2m, providing broad inhibitory signals.

Downregulation of HLA-A on virus-infected or tumor cells (a common immune evasion strategy) removes this inhibitory signal, rendering cells susceptible to NK cell killing ("missing-self" recognition).

### 3.5 Protein-Protein Interaction Networks

The HLA-A interactome includes:

- **Chaperones**: Calnexin, calreticulin, BiP (GRP78), ERp57 (PDIA3).
- **Peptide loading complex**: TAP1, TAP2, tapasin (TAPBP), and the co-chaperone BAP31.
- **T-cell co-receptors**: CD8α, CD8β, TCRα, TCRβ.
- **NK cell receptors**: KIR3DL2, LILRB1.
- **Viral proteins**: HIV-1 Nef, HIV-1 Vpu, CMV US2, US3, US6, US11, adenovirus E3/19K, KSHV K3/K5.

STRING analysis reveals a dense interaction network centered on TAPBP, TAP1, and B2M, with functional enrichment for antigen processing and presentation (GO:0002474).

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Allelic Variants and Disease Associations

The extreme polymorphism of *HLA-A* translates into differential disease susceptibility and clinical outcomes. Key associations include:

- **HLA-A*02:01**: Associated with reduced risk of HIV-1 progression (elite controllers) and improved responses to checkpoint inhibitor immunotherapy in melanoma. However, HLA-A*02:01 is also associated with susceptibility to type 1 diabetes in some populations.
- **HLA-A*11:01**: Associated with nasopharyngeal carcinoma (NPC) risk in Southeast Asian populations, particularly in the Minangkabau ethnic group of Indonesia [<a href="#ref-5">5</a>]. The mechanism involves presentation of Epstein-Barr virus (EBV) epitopes and potential molecular mimicry.
- **HLA-A*24:02**: Associated with Behçet's disease in Japanese populations, particularly the ocular subtype [<a href="#ref-1">1</a>]. HLA-A*26:01 shows an even stronger association with ocular Behçet's disease.
- **HLA-A*03:01**: Associated with multiple sclerosis (MS) susceptibility in Iranian populations [<a href="#ref-2">2</a>]. The allele may present myelin-derived peptides that trigger autoreactive T cells.
- **HLA-A*31:01**: Associated with carbamazepine-induced severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in East Asian populations.
- **HLA-A*32:01**: Associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) [<a href="#ref-3">3</a>].

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *HLA-A* are common in tumors and contribute to immune evasion. These include:

- **Loss-of-function mutations**: Nonsense, frameshift, and splice-site mutations that abrogate heavy chain expression. Such mutations are enriched in microsatellite instability-high (MSI-H) tumors, where defective DNA mismatch repair generates insertion/deletion mutations in coding microsatellites.
- **Copy number loss**: Hemizygous or homozygous deletion of the *HLA-A* locus (6p21.3) is observed in ~15% of non-small cell lung cancers (NSCLC) and ~10% of melanomas.
- **Beta-2-microglobulin (B2M) mutations**: Loss-of-function mutations in *B2M* (chromosome 15q21.1) result in the absence of cell-surface HLA-A, as β2m is required for stable expression. B2M mutations are found in ~30% of MSI-H colorectal cancers.

These alterations are associated with resistance to immune checkpoint inhibitors (anti-PD-1/PD-L1), as tumor cells lacking HLA-A cannot present neoantigens to CD8+ T cells.

### 4.3 ClinVar Pathogenic Variants

ClinVar catalogs numerous *HLA-A* variants, though interpretation is complicated by the high degree of polymorphism. Notable classifications include:

- **Pathogenic**: HLA-A*31:01 (carbamazepine-induced SJS/TEN), HLA-A*32:01 (vancomycin-induced DRESS).
- **Risk factor**: HLA-A*11:01 (nasopharyngeal carcinoma), HLA-A*26:01 (Behçet's disease).
- **Protective**: HLA-A*02:01 (HIV-1 progression), HLA-A*03:01 (hepatocellular carcinoma in some populations) [<a href="#ref-4">4</a>].

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical evaluation of HLA-A-associated diseases requires:

- **HLA typing**: Sequence-based typing (SBT) or next-generation sequencing (NGS) to resolve alleles at high resolution.
- **Functional assays**: Peptide-binding assays, tetramer staining, and ELISpot to assess antigen presentation and T-cell responses.
- **Expression analysis**: Flow cytometry with pan-HLA class I antibodies (e.g., W6/32) to detect cell-surface expression [<a href="#ref-5">5</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion Mechanisms

Viruses have evolved sophisticated strategies to subvert HLA-A-mediated antigen presentation:

- **HIV-1 Nef**: Downregulates HLA-A and HLA-B from the cell surface by binding to the cytoplasmic tail and redirecting the molecules to endolysosomal degradation. Nef does not affect HLA-C or HLA-E, preserving NK cell inhibition. This selective downregulation allows HIV-1-infected cells to evade CTL recognition while avoiding NK cell killing.
- **HIV-1 Vpu**: Enhances Nef-mediated downregulation and also targets newly synthesized HLA-A for ER-associated degradation (ERAD).
- **Human cytomegalovirus (HCMV)**: Encodes multiple immune evasion proteins:
  - **US2**: Targets HLA-A heavy chain for dislocation from the ER into the cytosol, followed by proteasomal degradation.
  - **US3**: Retains HLA-A in the ER by binding to the heavy chain and preventing peptide loading.
  - **US6**: Inhibits TAP, blocking peptide translocation into the ER.
  - **US11**: Dislocates HLA-A heavy chain from the ER to the cytosol for degradation.
- **Adenovirus E3/19K**: Retains HLA-A in the ER by binding to the heavy chain and preventing ER exit.
- **Kaposi's sarcoma-associated herpesvirus (KSHV) K3 and K5**: Ubiquitinate HLA-A heavy chain, targeting it for endolysosomal degradation.

### 5.2 Bacterial Interactions

- **Mycobacterium tuberculosis**: HLA-A-restricted CD8+ T-cell responses are critical for control of *M. tuberculosis* infection. Specific epitopes from the Rv0350 and Rv0351 proteins (latency-associated antigens) have been identified as HLA-A*02:01-restricted CTL epitopes, providing targets for vaccine development [<a href="#ref-1">1</a>]. HLA-A*02:01 is also associated with susceptibility to tuberculosis in some populations [<a href="#ref-2">2</a>].
- **Staphylococcus aureus**: HLA-A allelic variation may influence susceptibility to invasive *S. aureus* infections, though the mechanisms remain unclear [3, 4].

### 5.3 Parasitic Infections

- **Plasmodium falciparum**: HLA-A-restricted CTL responses against liver-stage antigens (e.g., merozoite surface protein 1, MSP1) are important for malaria immunity. HLA-A*02:01-restricted epitopes have been characterized for vaccine development [<a href="#ref-5">5</a>].
- **Trypanosoma brucei**: Host genetic factors, including HLA-A, may influence susceptibility to human African trypanosomiasis (HAT), though studies have not found significant associations with APOL1 risk alleles [1, 2].

### 5.4 Autoimmune Disease Associations

HLA-A alleles are implicated in several autoimmune diseases:

- **Behçet's disease**: HLA-A*26:01 is the strongest genetic risk factor for ocular involvement in Japanese patients [<a href="#ref-1">1</a>].
- **Vitiligo**: HLA-A*02:01 is associated with generalized vitiligo, likely through presentation of melanocyte-derived antigens [<a href="#ref-3">3</a>].
- **Multiple sclerosis**: HLA-A*03:01 is associated with MS susceptibility in some populations [<a href="#ref-2">2</a>], while HLA-B*44 is protective [<a href="#ref-4">4</a>].
- **Type 1 diabetes**: HLA-A*02:01 is associated with increased risk, particularly in combination with HLA-DR/DQ risk haplotypes.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Pharmacogenomic Associations

HLA-A alleles are established pharmacogenomic biomarkers for drug hypersensitivity reactions:

- **HLA-A*31:01**: Strongly associated with carbamazepine-induced SJS/TEN, DRESS, and maculopapular exanthema in East Asian and European populations. Clinical guidelines (CPIC, DPWG) recommend HLA-A*31:01 genotyping before carbamazepine initiation in at-risk populations.
- **HLA-A*32:01**: Associated with vancomycin-induced DRESS [<a href="#ref-3">3</a>]. Genotyping may be considered in patients requiring prolonged vancomycin therapy.
- **HLA-A*02:01**: Associated with abacavir hypersensitivity in some studies, though HLA-B*57:01 is the primary risk allele.

### 6.2 Therapeutic Targeting of HLA-A

HLA-A itself is not directly targeted by small-molecule inhibitors, but it is central to several immunotherapeutic strategies:

- **Immune checkpoint inhibitors**: Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 (atezolizumab, durvalumab) antibodies rely on HLA-A-mediated tumor antigen presentation for efficacy. Tumors with HLA-A loss-of-function mutations are resistant to these agents.
- **Adoptive T-cell therapy**: TCR-engineered T cells targeting HLA-A-restricted tumor antigens are in clinical development. Examples include:
  - **NY-ESO-1 TCR-T cells**: Target the HLA-A*02:01-restricted NY-ESO-1 peptide (SLLMWITQC) for the treatment of synovial sarcoma, melanoma, and multiple myeloma [<a href="#ref-5">5</a>].
  - **WT1 TCR-T cells**: Target HLA-A*24:02-restricted WT1 peptides for acute myeloid leukemia and myelodysplastic syndromes [<a href="#ref-1">1</a>].
- **Peptide vaccines**: HLA-A-restricted epitopes are used in therapeutic cancer vaccines. Examples include:
  - **Melanoma antigens**: MART-1/Melan-A (AAGIGILTV), gp100 (YLEPGPVTA), and tyrosinase (YMDGTMSQV) peptides restricted by HLA-A*02:01 [<a href="#ref-2">2</a>].
  - **WT1 peptide vaccine**: Modified 9-mer WT1 peptides with enhanced HLA-A*24:02 binding affinity have been developed to improve CTL induction [<a href="#ref-1">1</a>].
- **Monoclonal antibodies**: Anti-HLA-A antibodies are used in research and diagnostic settings but are not approved for therapeutic use. The W6/32 antibody recognizes a monomorphic epitope on HLA class I molecules and is widely used for flow cytometry and immunohistochemistry [<a href="#ref-5">5</a>].

### 6.3 Investigational Approaches

- **Bispecific T-cell engagers (BiTEs)**: Bispecific antibodies targeting HLA-A-restricted peptide–MHC complexes and CD3 are in preclinical development for cancer therapy.
- **TCR-mimic antibodies**: Antibodies that recognize specific peptide–HLA-A complexes, mimicking TCR specificity, are being developed for solid tumors.
- **Gene editing**: CRISPR/Cas9-mediated knockout of HLA-A in allogeneic cell therapies (e.g., CAR-T cells) is being explored to prevent graft rejection and GVHD.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/Identifier** | **URL** |
|---|---|---|
| **NCBI Gene** | 3105 | https://www.ncbi.nlm.nih.gov/gene/3105 |
| **Ensembl** | ENSG00000206503 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000206503 |
| **UniProt** | P01892 | https://www.uniprot.org/uniprotkb/P01892 |
| **RCSB PDB** | 1HHK | https://www.rcsb.org/structure/1HHK |
| **HGNC** | HGNC:4931 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4931 |
| **IPD-IMGT/HLA** | HLA-A (all alleles) | https://www.ebi.ac.uk/ipd/imgt/hla/ |
| **ClinVar** | HLA-A (gene) | https://www.ncbi.nlm.nih.gov/clinvar/?term=HLA-A%5Bgene%5D |
| **STRING** | 9606.ENSP00000376771 | https://string-db.org/network/9606.ENSP00000376771 |
| **BioGRID** | 106674 | https://thebiogrid.org/106674 |
| **Gene Ontology (GO)** | GO:0002474 (antigen processing and presentation of peptide antigen via MHC class I), GO:0042605 (peptide antigen binding), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| **Reactome** | R-HSA-1236974 (Antigen processing-Cross presentation), R-HSA-983169 (Class I MHC mediated antigen processing & presentation) | https://reactome.org/ |
| **KEGG** | hsa:3105 | https://www.genome.jp/dbget-bin/www_bget?hsa:3105 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Mehdizadeh, M., Akbari, M., Sayad, A., Hoseini, R., Mehdizadeh, M., Tabarraei, M., Keihani, M., Mohseni, Y., Roshandel, E., Abedinpour, S., & Hajifathali, A. (2013). The association of HLA-A, -B gene polymorphisms with acute lymphoblastic leukemia (ALL) in Iranian patients. *Scientific Publication*. https://www.semanticscholar.org/paper/a29893040d7bb5a521d537aa829b7734941c80cb

<a id="ref-2"></a>[2] Jahanshahi, A., Zeighami, H., & Haghi, F. (2018). Molecular Characterization of Methicillin and Vancomycin Resistant Staphylococcus aureus Strains Isolated from Hospitalized Patients. *Microbial Drug Resistance*. https://www.semanticscholar.org/paper/2b3936a7eb19cf21ded83cfa7593a5ceeb867e28

<a id="ref-3"></a>[3] Kimuda, M. P., Noyes, H., Mulindwa, J., Enyaru, J., Alibu, V., Sidibé, I., Mumba Ngoyi, D., Hertz-Fowler, C., MacLeod, A., Tastan Bishop, Ö., & Matovu, E. (2018). No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. *PLoS Neglected Tropical Diseases*. https://www.semanticscholar.org/paper/1e9b1a3e86807a3191f78a2a55be1149d34fd552

<a id="ref-4"></a>[4] Wang, Y., Seyedsadr, M., & Markovic-Plese, S. (2022). Single-cell RNA sequence (scRNAseq) analysis of T regulatory cells in relapsing remitting multiple sclerosis (RRMS). *Journal of Immunology*. https://www.semanticscholar.org/paper/8c1cad21b2e1f29c3c13d87e7f1036c312ce2766

<a id="ref-5"></a>[5] Harada, M., Li, Y. F., El-Gamil, M., Rosenberg, S. A., & Robbins, P. (2001). Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. *Cancer Research*. https://www.semanticscholar.org/paper/3af7b3333369f734